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Objectives.There have been advances in the identification and understanding ofmolecular subsets of lung cancer, defined by specific
oncogenic aberrations. Anumber of actionable genetic alterations have been identified, such as the epidermal growth factor receptor
(EGFR) mutation. We aimed to establish the reasons why patients were not undergoing EGFR mutation testing at the time of
histological diagnosis. Methods. The records of 70 patients with advanced adenocarcinoma of the lung managed through a single
multidisciplinary team at a single institution were reviewed. Data were collected on method of tumour sample collection, whether
this was sent for EGFR testing, and the result. Results. Seventy patients were identified. In 21/25 (84%) cases, cytological sampling
was sufficient for EGFR mutation analysis, compared with 40/45 (89%) cases with histological sampling. EGFR mutation testing
was not carried out in 22/70 (31.4%) patients.Therewas insufficient tumour sample for EGFR testing in 9/22 (40.9%) patients. Other
reasons for not testing included poor patient fitness and problems in the diagnostic pathway. Conclusions. In this series, cytological
tumour sampling was not the predominant reason why cancers failed to have EGFR mutation status established.
1. Introduction
Lung cancer represents a significant health problem. In
Europe in 2012, there were an estimated 410,000 new cases
diagnosed, and most patients present with advanced stage,
incurable disease [1].
In recent years, there have been advances in the iden-
tification and understanding of molecular subsets of lung
cancer, defined by specific oncogenic aberrations [2]. There
are a number of actionable genetic alterations that have been
identified.
Oral tyrosine kinase inhibitors (TKIs) have been shown to
prolong progression-free survival in patients with advanced
NSCLC harbouring a sensitising EGFR mutation compared
with doublet chemotherapy in a number of clinical trials [3–
5]. In addition, recent analysis of data from the LUX-LUNG 3
and LUX-LUNG 6 trials has shown that in patients with exon
19 deletions (the commonest sensitising EGFR mutation),
afatinib significantly prolongs overall survival in the first-
line setting in stage IIIB-IV NSCLC when compared with
doublet chemotherapy [3, 4]. The EML4-ALK translocation
protein is found in approximately 3–7% of adenocarcinomas
and 2–5% of NSCLC overall [2]. Crizotinib is an oral small
molecule TKI which specifically targets ALK, MET, and
ROS1. The PROFILE 1007 trial demonstrated a significantly
longer progression-free survival with Crizotinib compared
with chemotherapy in the second-line setting for patients
with advanced ALK positive NSCLC [6]. In addition, several
other genetic alterations have been identified. These include
ROS1, AKT, BRAF, FGFR,MET,MEK1, PTENRET, PIK3CA,
KRAS, andHER2 [2]. Treatments that target these alterations
are currently undergoing testing in clinical trials and may
have therapeutic application in the near future.Therefore, it is
imperative that adequate samples are acquired for molecular
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Table 1: Reasons why EGFR testing was not done.
𝑁 %
Insufficient sample for EGFR mutation testing 9 40.9
(i) Histological tumour sampling (6) (27.3)
(ii) Cytological tumour sampling (3) (13.6)
No sample sent (no documented reason) 10 45.5
Deemed not fit for treatment 2 9.1
Declined treatment 1 4.5
profiling to ensure patients receive optimum treatment and
to facilitate patients entering clinical trials.
There has been a drive in recent years to use minimally
invasive techniques to obtain sufficient tumour sample for
diagnosis in patients with advanced NSCLC. The National
Institute for Health and Clinical Excellence (NICE) rec-
ommend choosing the investigation which gives the most
information about diagnosis and staging with the least risk to
the patient [7]. In light of this, techniques such as endoscopic
bronchial ultrasound- (EBUS-) guided biopsy, bronchoscopy
with fine needle aspiration (FNA), and ultrasound-guided
biopsy of supraclavicular neck nodes have becomemore com-
monly used.These techniques provide cytological samples for
testing.Wehypothesised that this shift in diagnostic approach
may have led to a proportion of cases where molecular
analysis was not possible due to insufficient cancer DNA in
the tumour samples provided. To test this hypothesis, as well
as investigating other reasons why patients’ tumour samples
were not tested, we looked at the records of 70 consecutive
patients with advanced adenocarcinoma of the lungmanaged
through a single multidisciplinary team (MDT) in SEWales.
2. Materials and Methods
All patients diagnosed and treated through a single lung
cancer MDT (at a single institution) between January 1,
2012, and January 1, 2014, were identified using Cansic, an
electronic patient database record of all cancer patients in
Wales. Patients with stage III or IV NSCLC and a histological
or cytological diagnosis of adenocarcinoma were included in
the analysis. Squamous cell carcinoma cases were excluded;
at the time of the study there were no identified molecular
subsets that would benefit from a licensed targeted therapy,
so samples were not routinely tested. Data were collected
based on patient sex, date of birth, age at diagnosis, stage at
diagnosis, method of tumour sample collection, whether the
sample was sent for EGFR mutation testing, and the results
of testing. EGFR mutation analysis was carried out in the
All Wales Genetics Laboratory, University Hospital of Wales.
In patients where no EGFR mutation testing was performed,
the reason for this was recorded. No patients were tested for
the ALK translocation, as at the time of the study, no ALK-
targeting therapies were routinely funded.
3. Results
In total, 70 patients who fulfilled the criteria were identified
and all were included in the analysis. There were 42 females
and 28 males. The median age was 67 years (range 42–84
years). In total, 12/70 (17%) patients had stage IIIA disease,
5/70 (7%) had stage IIIB, and 53/70 (76%) had stage IV
disease. A histological sampling technique was used in 45/70
(64%) patients, and a cytological sampling technique was
used in 25/70 (36%) patients.
In total, 48/70 (68.6%) patients in this study diagnosed
with stage III/IV adenocarcinoma of the lung had EGFR
mutation testing. EGFR mutation testing was not carried out
in 22/70 (31.4%) patients (Table 1). In 13/22 (59.1%) of cases,
there was sufficient sample for EGFR mutation analysis, but
testing was not carried out, in 10/22 (45.5%) patients there
was no sample sent and no documented reason, 2/22 (9.1%)
patients were not fit for treatment, and 1/22 (4.5%) patient
declined treatment. In the remaining 9/22 (41%) patients,
there was insufficient sample for EGFR mutation testing.
Therefore, in total, sufficient tumour sample was acquired
for EGFR mutation analysis in 61/70 (87%) patients. In
21/25 (84%) cases, sufficient sample was acquired for EGFR
mutation analysis after a cytological sampling technique,
compared with 40/45 (89%) with a histological sampling
technique. There was insufficient sample for analysis in 9/70
(13%) patients. Of these, 3 patients had a sample obtained
from a CT guided biopsy, 2 had a bronchoscopic biopsy, 1
EBUS FNA of a node, 1 bronchial washing, 1 bone metastasis
biopsy, and 1 sample was a pleural fluid sample. The diagnos-
tic yield according to sampling method is shown in Table 2.
Wild type EGFR was identified in 41/48 (85.4%) of
patients tested. 7/48 (14.6%) tested patients had a sensitising
EGFR mutation.
4. Discussion
This is a retrospective real world study looking at the
proportion of patients with newly diagnosed stage III/IV
adenocarcinoma of the lungwhose diagnostic tumour sample
underwent successful EGFR mutation analysis. Treatment
decisions are now based not only on histological subtype but
increasingly on molecular profiling, most importantly EGFR
mutation status. The LUX-Lung 3 and 6 trials have shown
a significant overall survival benefit in the first-line setting
with the EGFR TKI afatinib in patients with the EGFR exon
19 deletion, highlighting the importance of adequate tumour
sampling to allow genetic analysis to be undertaken [3, 4].
In this cohort, 22/70 (31.4%) patients did not undergo
EGFR mutation testing. Our hypothesis was that this may
have been due to cytological tumour sampling resulting
in less tumour DNA for testing. In fact, results showed
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Table 2: Source of sample for diagnosis.
Sent for EGFR mutation testing Successful mutation analysis
𝑁 𝑁 % 𝑁 %
Histological 45 37 82 30 81
CT guided lung biopsy 17 14 82 11 79
Bronchoscopic biopsy 12 9 75 8 89
CT guided bone biopsy 3 3 100 3 100
Wedge resection 2 2 100 0 0
Excision biopsy neck node 2 2 100 2 100
Biopsy of metastasis 2 2 100 2 100
Lobectomy 1 1 100 1 100
VATS biopsy lung 1 0 0 0 0
Core biopsy node 1 1 100 1 100
Bone biopsy 3 2 67 1 33
Endoscopic biopsy of oesophagus 1 1 100 1 100
Cytological 25 22 88 20 91
Pleural fluid 11 10 91 9 90
EBUS TBNA node 9 8 89 8 100
Bronchial washings 2 1 50 0 0
CT guided FNA lung 1 1 100 1 100
EUS FNA node 1 1 100 1 100
FNA node 1 1 100 1 100
that the percentage of successful EGFR tests was similar in
the cytological (21/25, 84%) and histological (40/45, 88.9%)
sample groups.The similarity in successful mutation analysis
between the two groups effectively disproved the hypothesis
that the dominant reason for the lower than expected rate
of mutation analysis was a result of insufficient sample
from a cytological diagnostic techniques. This observation
is borne out in other published studies looking at methods
of acquiring sample in patients with lung cancer [8]. A
study by Jose´ et al. retrospectively assessed the methods
used to obtain diagnostic samples in 328 consecutive patients
diagnosed with lung cancer between 2007 and 2011. They
found that there had been a reduction in the number of
standard bronchoscopies and mediastinoscopies carried out
and a significant increase in EBUS-transbronchial needle
aspiration (TBNA) [9]. Jurado et al. reported on 56 patients
with adenocarcinoma, who underwent EBUS FNA, and
showed this is effective for molecular testing, providing
sufficient sample for testing in 82% of patients in the study
[10]. This is comparable to the rate seen in our series
using cytological diagnostic techniques. A recent systematic
review by Ellison et al. identified 33 studies reporting the
use of cytology for EGFR mutation testing, including FNA
samples obtained under CT guidance, endoscopic ultrasound
(EUS), and EBUS, which concluded that these samples can
be successfully assessed for EGFR mutations using various
techniques such as direct sequencing, real-time PCR, and
COLD-PCR [11]. Albanna et al. compared the yield for
702 diagnostic procedures for pathological classification,
of which 269 samples were also sent for EGFR mutation
analysis. They concluded that radiologically guided TBNA
provided a high yield for molecular analysis, but unguided
TBNA was of low utility, demonstrating the importance of
using radiological guidance when undertaking TBNA [12].
It is clear that in our cohort of patients themost significant
reason for samples not being tested for EGFR mutations was
failure in the process around requesting EGFR testing. One
way of minimising delays and simplifying the process to
ensure all relevant samples are tested is by introducing proto-
col driven EGFR testing. In other words all samples are sent
for EGFR mutation testing by the reporting histopathologist
irrespective of histologic subtype, disease stage, treatment
intent, or potential clinical trial participation. In this study,
patients were selected for EGFRmutation testing on the basis
of adenocarcinoma histology and advanced disease. In clini-
cal practice, our selection criteria for EGFR mutation testing
are very similar; all patients with nonsquamous NSCLC and
advanced incurable disease are tested. We do not routinely
test patients with squamous cell carcinoma as mutation rates
are reported to be very low. In addition,we donot test patients
with localised or locally advanced disease undergoing poten-
tially curative treatment because mutation status is highly
unlikely to change initial management. Clinical trials often
require central review of pathology or additional sample for
nonstandard tests. Diagnostic samples are often scanty and a
decision may have to be made whether to use the specimen
for immunohistochemical testing, EGFRmutation testing, or
central review at a clinical trials laboratory. For these reasons,
the decision whether to EGFRmutation test or not is made at
the MDT for a significant proportion of patients.
In ten patients, biopsy samples were not sent for EGFR
mutation analysis. This represents a significant proportion
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of our cohort. At the time of the study, there was no
method of tracking a sample through the process from
acquisition to EGFR mutation testing. In addition, the EGFR
mutation result is not automatically incorporated into the
biopsy pathology report. In these cases, it was not possible to
determine exactly where the pathway had broken down, and
we are therefore unable to comment onwhyEGFR testingwas
not carried out. In our opinion, a possible explanation is that
there were a proportion of cases where an assumption had
been made that the sample taken was insufficient for testing.
There is no defined standard for minimum sample require-
ment for EGFR mutation analysis. Guidelines from the
College of American Pathologists state that each laboratory
should establish the minimum proportion and number of
cancer cells needed for mutation detection during validation
and that pathologists should determine the adequacy of a
specimen by assessing cancer cell content, DNA quantity,
and quality [13]. Consequently, these decisions are inevitably
subjective and will vary between clinicians and laboratories.
It is known that EGFR mutation analysis can be carried
out on very small samples. A recent study showed that
successful mutation analysis could be carried out on samples
as small as 0.12mm2, containing less than 200 cells [14]. Our
practice now is to send even very small samples for mutation
analysis.
In two cases, EGFRmutation analysis was not carried out
due to the patients’ poor performance status (PS), in both
cases the World Health Organisation PS (WHO PS) was 3,
and the patient was deemed not fit for treatment. There is
evidence that very poor PS patients with an actionable EGFR
mutation do benefit from an EGFR TKI even if they are not
fit enough for treatment with chemotherapy [15]. It is now
standard practice for us to test patients with poor PS for
EGFRmutations, as the “Lazarus effect” in mutation positive
patients treated with EGFR TKI is well recognized [16].
As our understanding of the molecular mechanisms
underlying tumour pathogenesis increases, more targeted
therapies are becoming available for this group of patients.
Although molecular technologies will improve through gene
panel analysis, the requirement for sufficient sample for
increasingly complex molecular analyses will become more
important for effective treatment decisions. In the near
future, the use of circulating tumour DNA (ctDNA) as a
diagnostic sampling method may improve some of these
practical issues. ctDNA is shed from tumours into peripheral
blood during apoptosis, providing easy accessibility despite
minimal tumour DNA samples. The use of ctDNA allows
diagnostic analysis of targeted molecular biomarkers such as
EGFR without the requirement for a sample. This therefore
enables access to testing for those lung cancer patients who
do not have sufficient sample or have not been sampled
at all. However, this technology relies upon careful sample
handling, as ctDNA is highly degradable.The yield of ctDNA
for diagnostic analysis is limited and sufficient for EGFR but
may prove challenging with the requirement for gene panel
testing. The introduction of digital methodologies has now
significantly improved the sensitivity of analysis such that
false negatives are no longer a concern.The benefits of ctDNA
include less invasive sampling, with the option of easily
repeated samples, and this may be extended to sampling for
the detection of resistancemutations such as EGFR p.T790M.
ctDNA also avoids issues of sample heterogeneity which are
associated with small biopsies.
5. Conclusion
This study was carried out because of concerns around a
low EGFR mutation testing rate in patients with advanced
NSCLC potentially suitable for targeted therapy. Insufficient
sample acquisition was not the most significant reason for
the low testing rate seen; cytological sampling was almost
as effective as histological methods at acquiring adequate
sample for analysis. A greater problem was the pathway
for requesting EGFR mutation analysis, which meant that
appropriate patients were not being tested for the EGFR
mutation despite adequate sample and were being denied
the opportunity to have potentially effective treatment. We
recommend that all lung cancer MDTs review their local
EGFR mutation testing practice to ensure robust systems are
in place and patients are given every opportunity to receive
optimum treatment.
Conflicts of Interest
The authors have declared the following conflicts of inter-
est. Dr. Jason Francis Lester has received honoraria from
Boehringer Ingelheim, Pfizer, Roche, and Astra Zeneca. Dr.
Rhian Siaˆn Davies has received educational grants from
Boehringer Ingelheim and honoraria from Roche. Mr. Chris-
tian Smith has received honoraria from Pfizer and an edu-
cational grant from Novartis for collecting the data for this
study. Dr. Diane Parry has received honoraria from Roche
and Astra Zeneca.
References
[1] J. Ferlay, E. Steliarova-Foucher, J. Lortet-Tieulent et al., “Cancer
incidence and mortality patterns in Europe: estimates for 40
countries in 2012,” European Journal of Cancer, vol. 49, no. 6,
pp. 1374–1403, 2013.
[2] D. E. Gerber, L. Gandhi, and D. B. Costa, “Management and
future directions in non-small cell lung cancer with known
activating mutations,” American Society of Clinical Oncology
Educational Book, pp. e353–e365, 2014.
[3] L. V. Sequist, J. C.-H. Yang, N. Yamamoto et al., “Phase III
study of afatinib or cisplatin plus pemetrexed in patients with
metastatic lung adenocarcinoma with EGFR mutations,” Jour-
nal of Clinical Oncology, vol. 31, no. 27, pp. 3327–3334, 2013.
[4] Y.-L. Wu, C. Zhou, C.-P. Hu et al., “Afatinib versus cis-
platin plus gemcitabine for first-line treatment of Asian
patients with advanced non-small-cell lung cancer harbouring
EGFRmutations (LUX-Lung 6): an open-label, randomised
phase 3 trial,” The Lancet Oncology, vol. 15, no. 2, pp. 213–222,
2014.
[5] T. S. Mok, Y. Wu, S. Thongprasert et al., “Gefitinib or
carboplatin–paclitaxel in pulmonary adenocarcinoma,” The
New England Journal of Medicine, vol. 361, no. 10, pp. 947–957,
2009.
Lung Cancer International 5
[6] A. T. Shaw, D.-W. Kim, K. Nakagawa et al., “Crizotinib versus
chemotherapy in advanced ALK-positive lung cancer,”TheNew
England Journal of Medicine, vol. 368, no. 25, pp. 2385–2394,
2013.
[7] NICE,NICEClinical Guideline 121:TheDiagnosis andTreatment
of Lung Cancer, NICE, 2011.
[8] G. Da Cunha Santos and M. A. Saieg, “Preanalytic parameters
in epidermal growth factor receptor mutation testing for non-
small cell lung carcinoma: a review of cytologic series,” Cancer
Cytopathology, vol. 123, no. 11, pp. 633–643, 2015.
[9] R. J. Jose´, P. Shaw, M. Taylor et al., “Impact of EBUS-TBNA on
modalities for tissue acquisition in patients with lung cancer,”
QJM, vol. 107, no. 3, pp. 201–206, 2014.
[10] J. Jurado, A. Saqi, R. Maxfield et al., “The efficacy of EBUS-
guided transbronchial needle aspiration for molecular testing
in lung adenocarcinoma,” Annals of Thoracic Surgery, vol. 96,
no. 4, pp. 1196–1202, 2013.
[11] G. Ellison, G. Zhu, A. Moulis, S. Dearden, G. Speake, and R.
McCormack, “EGFR mutation testing in lung cancer: a review
of available methods and their use for analysis of tumour tissue
and cytology samples,” Journal of Clinical Pathology, vol. 66, no.
2, pp. 79–89, 2013.
[12] A. S. Albanna, G. Kasymjanova, C. Robitaille et al., “Com-
parison of the yield of different diagnostic procedures for
cellular differentiation and genetic profiling of non-small-cell
lung cancer,” Journal ofThoracic Oncology, vol. 9, no. 8, pp. 1120–
1125, 2014.
[13] N. I. Lindeman, P. T. Cagle, M. B. Beasley et al., “Molecular
testing guideline for selection of lung cancer patients for
EGFR and ALK tyrosine kinase inhibitors: guideline from the
College of American Pathologists, International Association
for the Study of Lung Cancer, and Association for Molecular
Pathology,” Journal of Thoracic Oncology, vol. 8, no. 7, pp. 823–
859, 2013.
[14] S. Scarpino, F. Pulcini, A. Di Napoli, M. Giubettini, and L.
Ruco, “EGFR mutation testing in pulmonary adenocarcinoma:
evaluation of tumor cell number and tumor percent in paraffin
sections of 120 small biopsies,” Lung Cancer, vol. 87, no. 1, pp.
8–13, 2015.
[15] A. Inoue, K. Kobayashi, K. Usui et al., “First-line gefitinib for
patients with advanced non-small-cell lung cancer harboring
epidermal growth factor receptor mutations without indication
for chemotherapy,” Journal of Clinical Oncology, vol. 27, no. 9,
pp. 1394–1400, 2009.
[16] C. J. Langer, “The ‘Lazarus Response’ in treatment-na¨ıve, poor
performance status patients with non-small-cell lung cancer
and epidermal growth factor receptor mutation,” Journal of
Clinical Oncology, vol. 27, no. 9, pp. 1350–1354, 2009.



















































 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
